ISIS PHARMACEUTICALS FILES PUBLIC OFFERING FOR 2 MILLION SHARES OF COMMON STOCK
ISIS PHARMACEUTICALS FILES PUBLIC OFFERING FOR 2 MILLION SHARES
OF COMMON STOCK
CARLSBAD, Calif., Nov. 5 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIP) announced today that it has filed with the Securities and Exchange Commission a registration statement for a proposed public offering of 2,000,000 shares of common stock.
Of the shares to be sold, 1,600,000 shares will be offered in the United States by an underwriting group managed by Lehman Brothers, PaineWebber Incorporated and Daiwa Securities America Inc., and 400,000 shares will be offered outside the United States by an international investment banking syndicate managed by Lehman Brothers International, PaineWebber International and Daiwa Europe Limited. Isis has also granted the underwriters an option to purchase up to an additional 300,000 shares to cover over-allotments, if any.
The company plans to use the net proceeds of the offering for research and development, including preclinical and clinical testing, production of compounds, facilities expansion and other general corporate purposes.
Isis Pharmaceuticals, Inc., based in Northern San Diego County is engaged in the research and development of a new class of pharmaceutical products based on antisense technology.
A copy of the preliminary prospectus may be obtained from the offices of Lehman Brothers, World Financial Center, American Express Tower, New York, N.Y. 10285 (in Europe, One Broadgate, London, England (EC2M7IIA)); PaineWebber Incorporated, 1285 Avenue of the Americas, New York, N.Y. 10019; and Daiwa Securities America Inc., One World Financial Center, 200 Liberty Street, New York, N.Y. 10281.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
/CONTACT: Yasunori Kaneko of Isis Pharmaceuticals, 619-931-9200; or Anthony J. Russo or Deborah J. Lawson of Noonan/Russo Communications, 212-979-9180, for Isis Pharmaceuticals/
(ISIP) CO: Isis Pharmaceuticals, Inc. ST: California IN: MTC SU: OFR SM-OS -- NY021 -- 1151 11/05/91 10:06 EST